Idioma:

24 weeks treatment with pegylated interferon alfa plus ribavirin may be possible in genotype 1 chronic hepatitis C patients with rapid virological response who have low pretreatment viremia

Moon, Sung Soo ; Kang, Hyoun Gu ; Seo, Jeong Ah ; Jung, Eun Uk ; Lee, Sang Heon ; Park, Sung Jae ; Lee, Youn Jae ; Seol, Sang Yong

The Korean journal of gastroenterology, 2010-07, Vol.56 (1), p.33-38 [Revista revisada por pares]

Korea (South)

Texto completo disponible

Citas Citado por

Acciones

Título:
24 weeks treatment with pegylated interferon alfa plus ribavirin may be possible in genotype 1 chronic hepatitis C patients with rapid virological response who have low pretreatment viremia
Autor: Moon, Sung Soo ; Kang, Hyoun Gu ; Seo, Jeong Ah ; Jung, Eun Uk ; Lee, Sang Heon ; Park, Sung Jae ; Lee, Youn Jae ; Seol, Sang Yong
Materias: Adult ; Aged ; Antiviral Agents - administration & dosage ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Genotype ; Hepacivirus - genetics ; Hepatitis C, Chronic - drug therapy ; Humans ; Interferon-alpha - administration & dosage ; Male ; Middle Aged ; Polyethylene Glycols - administration & dosage ; Recombinant Proteins ; Ribavirin - administration & dosage ; RNA, Viral - blood ; Viral Load ; Viremia - diagnosis
Es parte de: The Korean journal of gastroenterology, 2010-07, Vol.56 (1), p.33-38
Notas: ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Descripción: The standard treatment for chronic hepatitis C infected with hepatitis C virus (HCV) genotype 1 is a combination of pegylated interferon alfa and ribavirin over a 48 weeks period. It is unclear if 24 weeks treatment is possible for patients showing a rapid virological response (RVR) without compromising the sustained virological response (SVR) in Korea. Between June 2005 and September 2008, among patients chronically infected with the HCV genotype 1 who were treated with pegylated interferon alfa subcutaneously once weekly plus ribavirin based on body weight, 55 patients who had low pretreatment viral load (<600,000 IU/mL) and RVR were enrolled. A total of 55 patients were divided into 24 weeks treatment group (n=29) and the standard treatment group (n=26). The HCV RNA was quantitatively assessed before treatment, and after 12 weeks of treatment, and also qualitatively assessed after 4 weeks of treatment, at end of treatment (24 weeks), and 24 weeks after end of treatment. RVR was defined as undetectable HCV RNA at the 4 weeks of treatment. Among the 55 patients, SVR was achieved in 100% (29/29) of the patients in 24 weeks treatment and 96.2% (25/26) of the patients in the standard treatment (p=0.473). HCV genotype 1 infected patients with a low baseline HCV RNA concentration who become HCV RNA negative at week 4 may be treated for 24 weeks without compromising sustained virological response. However, an additional trial will be needed to optimize the treatment duration.
Editor: Korea (South)
Idioma: Coreano

Enlaces

View this record in MEDLINE/PubMed

Volver a la lista de resultados

Anterior Resultado 6 Siguiente Ir a la siguiente página

Realización: Logos de Redes Sociales:

24 weeks treatment with pegylated interferon alfa plus ribavirin may be possible in genotype 1 chronic hepatitis C patients with rapid virological response who have low pretreatment viremia

Moon, Sung Soo ; Kang, Hyoun Gu ; Seo, Jeong Ah ; Jung, Eun Uk ; Lee, Sang Heon ; Park, Sung Jae ; Lee, Youn Jae ; Seol, Sang Yong

Korea (South)

Buscando en bases de datos remotas, por favor espere